Skip to main content
. 2014 Mar 14;20(10):2695–2703. doi: 10.3748/wjg.v20.i10.2695

Table 1.

Characteristics of the included studies and patients on cytomegalovirus in ulcerative colitis

Ref. Year of publication Type Design n
Included patients Severity criteria Method of diagnosis Anti-viral tx Follow-up (mo) Short-term colectomy rate
Long-term colectomy rate
TX C TX C TX C
Omiya et al[8] 2010 Full P1 10 10 Moderate to severe UC Seo’s score Tissue PCR (IHC/HE -) GCV 12 0/10 0/10 3/10 0/10
Zeki et al[9]1 2010 Abstract R2 7 10 UC (no severity data) NA HE/IHC+ GCV-5, 12 4/7 7/10 4/7 7/10
VGCV-2
Maconi et al[10]3 2011 Abstract R2 6 14 Moderate to severe UC Mayo/Baron score HE/IHC+ GCV 12 0/6 0/14 0/6 2/13
Criscuoli et al[17] 2011 Full P1 7 21 Moderate to severe UC Truelove/Witts IHC +, pp65+ GCV-5 FC-2 12 2/7 4/21 2/7 4/18
Kim et al[12] 2012 Full P1 14 17 Moderate to severe UC Mayo/Baron score HE/IHC/PCR+ GCV hospitalization 3/14 0/17 NA NA
Roblin et al[13]3 2011 Full P1 8 8 Moderate to severe UC, failure of CS +rescue therapy (IFX/CSA) Mayo qPCR, IHC/HE- GCV ≥ 10 1/8 2/8 3/8 2/8
Al-Zafiri et al[14]3 2012 Full R2 7 8 Hospitalized UC NA IHC/HE+ GCV hospitalization 3/7 0/8 NA NA
Maruyama et al[15] 2012 Abstract R2 4 12 Moderate to severe UC NA IHC/HE+ GCV Hospitalization 3/4 0/12 NA NA
Kopylov et al[16] 2013 Full R2 7 6 UC NA IHC/HE+ GCV-6 VGCV-1 13 1/7 0/6 3/7 0/6
1

P: prospective design;

2

R: retrospective design;

3

Some of the data was obtained through personal communication; TX: Patients treated with antivirals; C: Patients who did not receive antivirals. PCR: Polymerase chain reaction; qPCR: Quantitative PCR; IHC: Immunohistochemistry; HE: Hematoxylin-eosin staining; pp65: Antigenemia; GCV: Gancyclovir; VGCV: Valgancyclovir; FC: Foscarnet. Short -term outcome- during the initial hospitalization or within 30 d of the diagnosis; long-term outcome- > 3 mo after the initial hospitalization.